Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity lowered its price target for the telehealth firm from $68 to $30 on February 10, retaining a Buy rating on HIMS shares. Novo claimed that the “unlawful mass marketing” of its semaglutide medications in unapproved forms constituted patent infringement. The lawsuit comes after Hims & Hers Health, Inc. (NYSE:HIMS) made a brief announcement and then changed its position on compounded oral semaglutide being available on its marketplace.

Additionally, the FDA has declared its intention to limit the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded medications widely distributed by companies, specifically Hims & Hers Health, Inc. (NYSE:HIMS). According to analyst Maria Ripps, though the lawsuit increases operational risk, the firm is not yet changing its estimates.

Hims & Hers Health, Inc. (NYSE:HIMS) is a consumer-focused telehealth company. It provides personalized healthcare and wellness services through a digital platform that connects patients with licensed medical professionals. The company offers treatments across various categories, including sexual health, mental health, dermatology, and primary care.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None.